On Saturday 10th July, medac are holding a Satellite Symposium at the European Assocation of Urology.
The event will be hosted by Medscape and will cover the topic of ‘Expert Insights: Best Practices for Managing Intermediate-Risk and High-Risk NMIBC’.
Bacillus Calmetter Guerin (BCG, for intravesical immunotherapy) and Mitomycin C (MMC, for intravesical chemotherapy) have both been used for decades in the management of patients with non-muscle-invasive bladder cancer (NMIBC). Recent data has improved the understanding of clinical efficacy of both intravesical agents (Antonelli et al. PNAS 2020, Oresta et al. Sci Transl Med 2021).
Additionally, new EAU NMIBC Guidelines (2021) have introduced 4 NMIBC prognostic factor risk groups: low, intermediate, high and very high risk.
The symposium will subsequently cover how to risk-stratify NMIBC patients for risk-adapted therapy – and will focus largely on intermediate and high-risk patient groups.
The session will end with a live Q&A which will give attendees the opportunity to discuss current challenges in the management of NMIBC patients.
For more information, click here: https://scientific-programme.uroweb.org/eau21
(Select option ‘sponsored programme’ on Saturday 10th July).